George Topalov

George Topalov has a significant background in medicinal chemistry, with extensive experience in the biopharmaceutical industry. George is currently working as the Director of Medicinal Chemistry at Sionna Therapeutics since April 2022. Prior to that, George held the position of Senior Research Investigator at Knopp Biosciences LLC for ten years, from February 2012 to April 2022. George also worked as a Preclinical Science Consultant at ARCA biopharma, Inc. from September 2011 to January 2012. George's expertise includes leading chemistry efforts, conducting FTO analysis, discovering novel antagonists, and contributing to clinical development. George has co-developed a c-FMS kinase inhibitor series and initiated a medicinal chemistry effort on mTOR kinase. George has a track record of discovering and developing promising drug candidates, including Tucatinib and ARRY-543, for breast cancer indications. Additionally, they have collaborated on small molecule library projects and demonstrated proficiency in designing and synthesizing inhibitors.

George Topalov attended Dartmouth College from 1991 to 1995, where they obtained a Bachelor of Science with Honors in Chemistry. Following that, they pursued further education at Harvard University from 1995 to 2001, completing their PhD in Chemistry.